PL359602A1 - Sposoby hamowania wzrostu nowotworu mózgu - Google Patents

Sposoby hamowania wzrostu nowotworu mózgu

Info

Publication number
PL359602A1
PL359602A1 PL00359602A PL35960200A PL359602A1 PL 359602 A1 PL359602 A1 PL 359602A1 PL 00359602 A PL00359602 A PL 00359602A PL 35960200 A PL35960200 A PL 35960200A PL 359602 A1 PL359602 A1 PL 359602A1
Authority
PL
Poland
Prior art keywords
brain tumor
tumor growth
methods
inhibiting brain
brain
Prior art date
Application number
PL00359602A
Other languages
English (en)
Other versions
PL202082B1 (pl
Inventor
Walter E. Laug
Original Assignee
Childrens Hospital Los Angeles
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26815994&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL359602(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Childrens Hospital Los Angeles filed Critical Childrens Hospital Los Angeles
Publication of PL359602A1 publication Critical patent/PL359602A1/pl
Publication of PL202082B1 publication Critical patent/PL202082B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
PL359602A 1999-02-01 2000-01-26 Zastosowanie antagonisty integryny PL202082B1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11812699P 1999-02-01 1999-02-01
US09/489,391 US6521593B1 (en) 1999-02-01 2000-01-21 Methods for inhibiting brain tumor growth

Publications (2)

Publication Number Publication Date
PL359602A1 true PL359602A1 (pl) 2004-08-23
PL202082B1 PL202082B1 (pl) 2009-05-29

Family

ID=26815994

Family Applications (1)

Application Number Title Priority Date Filing Date
PL359602A PL202082B1 (pl) 1999-02-01 2000-01-26 Zastosowanie antagonisty integryny

Country Status (21)

Country Link
US (2) US6521593B1 (pl)
EP (1) EP1150714B1 (pl)
JP (1) JP4708568B2 (pl)
KR (1) KR100704139B1 (pl)
CN (2) CN1191858C (pl)
AT (1) ATE395934T1 (pl)
AU (2) AU775064B2 (pl)
BR (1) BR0007875A (pl)
CA (1) CA2360146C (pl)
CZ (1) CZ301480B6 (pl)
DE (1) DE60038951D1 (pl)
DK (1) DK1150714T3 (pl)
ES (1) ES2304942T3 (pl)
HU (1) HU230025B1 (pl)
MX (1) MXPA01007765A (pl)
NO (1) NO329695B1 (pl)
PL (1) PL202082B1 (pl)
PT (1) PT1150714E (pl)
RU (1) RU2377017C2 (pl)
SK (1) SK287326B6 (pl)
WO (1) WO2000044404A2 (pl)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000040597A1 (en) * 1999-01-06 2000-07-13 University Of Southern California Method and composition for angiogenesis inhibition
US7288390B2 (en) * 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
US7163681B2 (en) 2000-08-07 2007-01-16 Centocor, Inc. Anti-integrin antibodies, compositions, methods and uses
US7829087B2 (en) 2001-07-09 2010-11-09 Elan Pharmaceuticals, Inc. Methods of treating cognitive impairment
AU2002312566A1 (en) 2001-07-09 2003-01-29 Elan Pharmaceuticals, Inc. Methods of inhibiting amyloid toxicity
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
US7365167B2 (en) * 2001-11-26 2008-04-29 Cell Matrix, Inc. Humanized collagen antibodies and related methods
US7390885B2 (en) * 2001-11-26 2008-06-24 Cell Matrix, Inc. Humanized collagen antibodies and related methods
US20070185077A1 (en) * 2003-07-15 2007-08-09 Washington University Methods of treating, preventing and inhibiting cancer metastasis and tumor formation
US8668926B1 (en) 2003-09-15 2014-03-11 Shaker A. Mousa Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof
US9198887B2 (en) 2003-09-15 2015-12-01 Nanopharmaceuticals Llc Thyroid hormone analogs and methods of use
US8071134B2 (en) * 2003-09-15 2011-12-06 Ordway Research Institute, Inc. Thyroid hormone analogs and methods of use
CA2539288C (en) * 2003-09-15 2015-05-12 Shaker A. Mousa Thyroid hormone analogs and methods of use
ITRM20040105A1 (it) * 2004-02-27 2004-05-27 Tecnogen Scpa Anticorpo monoclonale antitenascina umana.
US9498536B2 (en) 2005-09-15 2016-11-22 Nanopharmaceuticals Llc Method and composition of thyroid hormone analogues and nanoformulations thereof for treating anti-inflammatory disorders
US10130686B2 (en) 2005-09-15 2018-11-20 Nanopharmaceuticals Llc Method and composition of thyroid hormone analogues and nanoformulations thereof for treating inflammatory disorders
US20090022806A1 (en) * 2006-12-22 2009-01-22 Mousa Shaker A Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists and formulations and uses thereof
WO2007035612A2 (en) 2005-09-16 2007-03-29 Ordway Research Institute, Inc. Polyphenol conjugates as rgd-binding compounds and methods of use
EP2332984A3 (en) * 2005-09-30 2011-10-12 Universiteit Maastricht Tumor angiogenesis associated genes and a method for their identification
EP2054442A2 (en) * 2006-06-14 2009-05-06 Cell-Matrix, Inc. Denatured collagen peptides and uses thereof
RU2009107277A (ru) 2006-08-03 2010-09-10 Астразенека Аб (Se) АНТИТЕЛА, НАЦЕЛЕННЫЕ НА αVβ6, И ИХ ПРИМЕНЕНИЕ
AU2007353426A1 (en) * 2006-12-22 2008-11-20 Albany College Of Pharmacy And Health Sciences Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof
US20110243927A1 (en) * 2007-08-24 2011-10-06 University Health Network Methods of inhibiting tumor growth using beta 5 integrin antagonists
WO2010072348A1 (en) 2008-12-23 2010-07-01 Merck Patent Gmbh Biomarkers for inhibitors with anti-angiogenic activity
US20100159021A1 (en) * 2008-12-23 2010-06-24 Paul Davis Small Molecule Ligands of the Integrin RGD Recognition Site and Methods of Use
US9180107B2 (en) * 2009-03-31 2015-11-10 Nanopharmaceuticals Llc Combination treatment of cancer with cetuximab and tetrac
CN101659694B (zh) * 2009-05-06 2012-12-12 河北科技大学 抗肿瘤环五肽化合物及其制备方法
EP2442800B1 (en) 2009-06-17 2019-04-24 NanoPharmaceuticals LLC Nanoparticle and polymer formulations for thyroid hormone, analogs, antagonists, and formulations and uses thereof
EP2595616B1 (en) 2010-06-30 2016-04-13 Galderma Research & Development Use of alpha-adrenergic receptor agonist for preventing or treating skin tumor
US8802240B2 (en) 2011-01-06 2014-08-12 Nanopharmaceuticals Llc Uses of formulations of thyroid hormone analogs and nanoparticulate forms thereof to increase chemosensitivity and radiosensitivity in tumor or cancer cells
CN102145161A (zh) * 2011-04-07 2011-08-10 中国药科大学 整合素阻断剂在制备治疗肿瘤药物中的应用
JP6426001B2 (ja) 2011-11-17 2018-11-21 グリア エスピー ゼット．オー．オー． 神経膠腫を治療するための組成物および方法
CN102417540A (zh) * 2011-11-21 2012-04-18 中国药科大学 一种聚乙二醇修饰的整合素阻断剂hm-3及其应用
US20170000905A1 (en) * 2015-06-30 2017-01-05 Mousera, Inc Device and method of personalized medicine
JP7074749B2 (ja) 2016-06-07 2022-05-24 ナノファーマシューティカルズ エルエルシー αｖβ３インテグリン甲状腺アンタゴニストにコンジュゲートした非開裂性ポリマー
US10328043B1 (en) 2018-04-11 2019-06-25 Nanopharmaceuticals, Llc. Composition and method for dual targeting in treatment of neuroendocrine tumors
US11351137B2 (en) 2018-04-11 2022-06-07 Nanopharmaceuticals Llc Composition and method for dual targeting in treatment of neuroendocrine tumors
WO2020030954A1 (en) 2018-08-09 2020-02-13 Integrative Medicine Clinic, Sia Theranostics-like protein sanps conjugated to integrin and pmsa targeting peptides and therapy of prostate cancer
RU2709215C1 (ru) * 2019-09-12 2019-12-17 Федеральное государственное бюджетное учреждение науки "Федеральный исследовательский центр "Институт катализа им. Г.К. Борескова Сибирского отделения Российской академии наук" (ИК СО РАН) Способ подавления роста опухолей глиального происхождения
US10961204B1 (en) 2020-04-29 2021-03-30 Nanopharmaceuticals Llc Composition of scalable thyrointegrin antagonists with improved blood brain barrier penetration and retention into brain tumors
US11723888B2 (en) 2021-12-09 2023-08-15 Nanopharmaceuticals Llc Polymer conjugated thyrointegrin antagonists

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2123338C1 (ru) * 1990-06-15 1998-12-20 Сайтел Корпорейшн Фармацевтическая композиция на основе медиатора межклеточной адгезии (варианты), способ ингибирования межклеточной адгезии, способ лечения воспалительного заболевания, способ анализа тестируемого соединения на способность ингибировать клеточную адгезию, способ получения соединения
US5753230A (en) * 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
ATE244306T1 (de) * 1994-12-20 2003-07-15 Merck Patent Gmbh Monoklonaler antikörper gegen das alpha-v- integrin
DE19534177A1 (de) * 1995-09-15 1997-03-20 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
DE19613933A1 (de) * 1996-04-06 1997-10-09 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
EP0907661A4 (en) * 1996-05-31 2000-07-26 Scripps Research Inst METHODS AND COMPOSITIONS FOR INHIBITING ALPHA-V-BETA5 MEDIATED ANGIOGENESIS.
AU729869B2 (en) * 1997-01-17 2001-02-15 Merck & Co., Inc. Integrin antagonists
US6590079B2 (en) * 1997-01-30 2003-07-08 Ixsys, Incorporated Anti-αvβ3 recombinant human antibodies, nucleic acids encoding same
US6160099A (en) * 1998-11-24 2000-12-12 Jonak; Zdenka Ludmila Anti-human αv β3 and αv β5 antibodies
CZ20002269A3 (cs) * 1998-12-14 2001-01-17 Merck & Co., Inc. Látky antagonizující receptor íntegrinu

Also Published As

Publication number Publication date
HU230025B1 (hu) 2015-05-28
CA2360146A1 (en) 2000-08-03
DK1150714T3 (da) 2008-08-18
CN1355711A (zh) 2002-06-26
SK287326B6 (sk) 2010-07-07
SK10622001A3 (sk) 2002-04-04
CN1332713C (zh) 2007-08-22
JP2002535375A (ja) 2002-10-22
CN1660426A (zh) 2005-08-31
AU2737900A (en) 2000-08-18
AU2004220756B2 (en) 2007-05-10
CZ301480B6 (cs) 2010-03-17
PT1150714E (pt) 2008-07-30
WO2000044404A2 (en) 2000-08-03
KR20020001726A (ko) 2002-01-09
AU775064B2 (en) 2004-07-15
CN1191858C (zh) 2005-03-09
US20030157098A1 (en) 2003-08-21
NO20013750D0 (no) 2001-07-31
JP4708568B2 (ja) 2011-06-22
CZ20012793A3 (cs) 2002-03-13
HUP0105155A3 (en) 2004-08-30
ATE395934T1 (de) 2008-06-15
PL202082B1 (pl) 2009-05-29
RU2005107614A (ru) 2006-08-27
MXPA01007765A (es) 2003-06-04
ES2304942T3 (es) 2008-11-01
EP1150714A2 (en) 2001-11-07
RU2377017C2 (ru) 2009-12-27
EP1150714B1 (en) 2008-05-21
KR100704139B1 (ko) 2007-04-09
WO2000044404A3 (en) 2000-11-30
NO329695B1 (no) 2010-12-06
NO20013750L (no) 2001-09-28
CA2360146C (en) 2013-05-21
BR0007875A (pt) 2002-02-13
US6521593B1 (en) 2003-02-18
AU2004220756A1 (en) 2004-11-11
DE60038951D1 (de) 2008-07-03
HUP0105155A2 (hu) 2002-04-29

Similar Documents

Publication Publication Date Title
MXPA01007765A (es) Metodos para inhibir el crecimiento de tumores en el cerebro.
IL151032A0 (en) Integrin antagonists
ZA987491B (en) Naphthyridinones for inhibiting protein tyrosine kinase and cell cycle kinase mediated cellular proliferation
EP1100870A4 (en) ENHANCING CARDIAC FUNCTIONING BY TRANSPLANTATION OF MESENCHYMAL STEM CELLS
MX9604145A (es) Metodos y composiciones utiles para la inhibicion de angiogenesis.
PL347128A1 (en) Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
GB0103668D0 (en) Methods and clinical devices for the inhibition or prevention of mammalian cell growth
GB2393735B (en) Cell culture method for obtaining prostate-like acini
PL341050A1 (en) Heterocyclic cytoxic agents
WO2001007028A3 (en) The use of retinoid receptor antagonists in the treatment of prostate carcinoma
EP1352055A4 (en) MAP KINASE INTEGRIN BINDING DOMAIN
ZA200500423B (en) Use of urease for inhibiting cancer cell growth
IL149416A0 (en) Human enzymes of the metalloprotease family
WO2004003152A3 (en) Sos1 inhibitors
EP1047942A4 (en) METHODS AND COMPOSITIONS FOR IDENTIFYING GROWTH FACTORS, GROWTH FACTORS AND INHIBITORS MIMETICS
ZA978494B (en) Method for inhibiting the growth of mammalian cells.
WO2005032595A3 (en) Methods and compositions for the inhibition of stat5 in prostate cancer cells
IL154974A0 (en) Inhibition of the growth factor dependency of tumor cells
AU2002252950A1 (en) Protein kinase d inhibitors and protein kinase 2 inhibitors as agents for inhibiting tumour cells and for stimulating angiogenesis
WO2003062197A3 (en) Nek2 inhibitors
MY117925A (en) Compounds for the inhibition of farnesyl protein transferase.
MXPA00006072A (es) Metodos y composiciones para inhibir el crecimiento de celulas tumorales.
AU4315300A (en) Method for inducing the cell death of nerve cell line, method for screening compound inhibiting or promoting the cell death of nerve cells, and cell death inhibitor and promoter for nerve cells
ZA200110213B (en) The use of the protein UK 114 for inhibiting organ transplant rejection.
GB0302763D0 (en) Potential growth factors from the human tumour cell line ht1080